Wave Life Sciences Pte. Ltd ( (WVE) ) has released its Q3 earnings. Here is a breakdown of the information Wave Life Sciences Pte. Ltd ...

Truist analyst Joon Lee raised the firm’s price target on Wave Life Sciences (WVE) to $36 from $17 and keeps a Buy rating on the shares.

Despite a net loss, WAVE Life Sciences Ltd (WVE) showcases promising clinical progress and a strengthened financial position ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...

The dystrophin expression was quantified from two isoforms consistent with those observed in Duchenne muscular dystrophy ...

Sarepta has stopped developing SRP-5051, its exon 51-skipping therapy for Duchenne MD, due to long-term safety concerns and ...

“We need help from other people,” pleaded Pavlina. “We saw videos from the children who were already there, it [the treatment ...

There is no shortage of ASX healthcare companies with upcoming catalysts – a focal point for investors. ... Read More The ...

TORONTO, November 13, 2024--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving ...